# Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

> **NCT05932667** · PHASE2 · TERMINATED · sponsor: **Institut Curie** · enrollment: 1 (actual)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Milademetan
- **BEHAVIORAL:** Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)

## Key facts

- **NCT ID:** NCT05932667
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-12
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Financial partner providing study drug could no longer support the trial
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932667, "Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05932667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*